Viewing Study NCT04014205


Ignite Creation Date: 2025-12-25 @ 3:33 AM
Ignite Modification Date: 2026-02-17 @ 7:22 PM
Study NCT ID: NCT04014205
Status: UNKNOWN
Last Update Posted: 2023-04-18
First Post: 2019-06-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module